Enrollment Closedjsukhram2020-05-19T19:10:26+00:00
| # | Category | Status | Study |
| 1 | HIV | Enrollment Closed | MK8591A-018 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in Participants with HIV-1 Virologically Suppressed on Biktarvy Major Inclusion/Exclusion Criteria:
|
| 2 | HIV | Enrollment Closed | MK8591A-017 A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in participants with HIV-1 Virologically Suppressed on Antiretroviral Therapy (ART). Major Inclusion/Exclusion Criteria:
|
| 3 | HIV | Enrollment Closed | MK1439-018 A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects |
| 4 | HIV | Enrollment Closed | GS-US-292-1825 Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis |
| 5 | HIV | Enrollment Closed | GS-US-292-1824 Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I |
| 6 | HIV | Enrollment Closed | GS-US-382-3961 Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated HIV-1 Infected Controllers |
| 7 | HIV | Enrollment Closed | Frontier ABT-3BNC117201 Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL) |
| 8 | HIV | Enrollment Closed | ViiV 200056 A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects |
| 9 | HIV | Enrollment Closed | ViiV AI438-047/205888 Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients |
| 10 | HIV | Enrollment Closed | Janssen TMC114IFD3013 Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants |
| 11 | HIV | Enrollment Closed | Janssen TMC114FD2HTX3001 A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects |
| 12 | HIV | Enrollment Closed | GS-US-380-1490 Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults |
| 13 | HIV | Enrollment Closed | GS-US-380-1489 Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults |
| 14 | HIV | Enrollment Closed | ViiV 205543 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2) |
| 15 | HIV | Enrollment Closed | ViiV 204861 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1) |
| 16 | HIV | Enrollment Closed | ViiV 201585 Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults |
| 17 | HIV | Enrollment Closed | CytoDyn PRO140_CD03 Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection |
| 18 | HIV | Enrollment Closed | GS-US-380-1474 B/F/TAF FDC in HIV-1 Infected Virologically Suppressed Adolescents and Children |
| 19 | HIV | Enrollment Closed | GS-US-380-4030 Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Adults Who Are Virologically Suppressed |
| 20 | HIV | Enrollment Closed | ViiV 204862 Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO) |
| 21 | HIV | Enrollment Closed | ViiV 207966 Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults |
| 22 | HIV | Enrollment Closed | ViiV 209035 Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)- Positive Subjects From the LATTE Study |
| 23 | HIV | Enrollment Closed | GS-US-380-4580 Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants |
| 24 | HIV | Enrollment Closed | 212355 (STAT) Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults Major Inclusion/Exclusion Criteria:
|
| 25 | HIV | Enrollment Closed | GS-US-200-4072Opened 11/14/2018 Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults Major Inclusion/Exclusion Criteria
|
| 26 | Other | Enrollment Closed | GS-US-412-2055 Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER) |